Rome, Italy

Gianluca Gostoli

This inventor holds 2 USPTO granted patents. Top assignee: Mediolanum Farmaceutici. Active years: 1994-1995.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1994-1995

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gianluca Gostoli: Innovator in Cholinesterase Inhibitors

Introduction

Gianluca Gostoli is a notable inventor based in Rome, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cholinesterase activity inhibitors. With a total of 2 patents, his work is recognized for its potential impact on medical treatments.

Latest Patents

Gianluca's latest patents include a process for preparing aminoalkylcarbamic esters of eseroline. These compounds are designed to serve as cholinesterase activity inhibitors, which are crucial in treating various neurological conditions. The general formula for these esters is defined in his patents, where R represents an amine selected from a specific group, and n, R1, R2, R3, and R4 are detailed in the accompanying text.

Career Highlights

Gianluca is currently employed at Mediolanum Farmaceutici S.p.a., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to advancing medical science through the development of effective therapeutic agents.

Collaborations

Some of his coworkers include Maria Alessandra Alisi and Mario Brufani, who contribute to the collaborative environment at Mediolanum Farmaceutici S.p.a. Their teamwork enhances the research and development efforts within the company.

Conclusion

Gianluca Gostoli's contributions to the field of pharmaceuticals, particularly through his patents on cholinesterase inhibitors, highlight his role as an influential inventor. His ongoing work at Mediolanum Farmaceutici S.p.a. promises to further advance medical treatments and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…